3D-printed solid oral dosage forms for mental and neurological disorders: recent advances and future perspectives.

Autor: Wojtyłko M; Chair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, Poznań, Poland.; School of Pharmacy, Queen's University Belfast, Belfast, UK., Lamprou DA; School of Pharmacy, Queen's University Belfast, Belfast, UK., Froelich A; Chair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, Poznań, Poland., Kuczko W; Institute of Materials Technology, Faculty of Mechanical Engineering, Poznan University of Technology, Poznan, Poland., Wichniarek R; Institute of Materials Technology, Faculty of Mechanical Engineering, Poznan University of Technology, Poznan, Poland., Osmałek T; Chair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, Poznań, Poland.

Publikováno v: Expert opinion on drug delivery [Expert Opin Drug Deliv] 2024 Nov; Vol. 21 (11), pp. 1523-1541. Date of Electronic Publication: 2023 Dec 11.

Selecting appropriate excipients for paediatric dosage form - Paediatric excipients risk assessment (PERA) framework - Part 1.

Autor: Salunke S; European Paediatric Formulation Initiative (EUPFI), University College London School of Pharmacy, London WC1N 1AX, UK. Electronic address: s.salunke@ucl.ac.uk., Agrawal A; Novo Nordisk Inc., 300 North Beacon Street, Suite 501, Watertown, MA 02472, USA. Electronic address: vagr@novonordisk.com., Walsh J; Jenny Walsh Consulting, Nottingham, UK. Electronic address: jenny@jennywalshconsulting.com., Nunn A; University of Liverpool, Department of Women's and Children's Health, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool L8 7SS, UK. Electronic address: tnunn100@hotmail.com., Hughes K; IPEC (International Pharmaceutical Excipients Council) and Colorcon Ltd, Dartford, UK. Electronic address: KHughes@colorcon.com., Kuehl P; F. Hoffmann La Roche AG, Grenzacher Str. 124, CH-4070 Basel, Switzerland., Caivano G; Chiesi Farmaceutici S.p.A., Largo Francesco Belloli 11/A, 43122 Parma, Italy. Electronic address: g.caivano@chiesi.com., Clapham D; Independent Pharmaceutical Consultant, Bishops Stortford, UK. Electronic address: david.clapham@ntlworld.com., Thompson K; Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA. Electronic address: karen_thompson@merck.com., Rumondor A; Bristol Myers Squibb, One Squibb Drive, New Brunswick, NJ 08901, USA. Electronic address: Alfred.Rumondor@bms.com., Enright B; Abbvie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA. Electronic address: Brian.Enright@abbvie.com., Sherratt P; Bristol Myers Squibb, 556 Morris Avenue, Summit, NJ 07901, USA. Electronic address: Philip.Sherratt@bms.com.

Publikováno v: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2024 Oct; Vol. 203, pp. 114458. Date of Electronic Publication: 2024 Aug 17.

Application of 3D printing on the design and development of pharmaceutical oral dosage forms.

Autor: Paccione N; TECNALIA, Basque Research and Technology Alliance (BRTA), Leonardo Da Vinci 11, 01510 Miñano, Spain; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain, Guarnizo-Herrero V; Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá de Henares, Ctra Madrid-Barcelona Km 33, 600 28805 Madrid, Spain, Ramalingam M; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain; Bioaraba Health Research Institute, Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain.; IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain; School of Basic Medical Sciences, Binzhou Medical University, Yantai 264003, People's Republic of China, Larrarte E; TECNALIA, Basque Research and Technology Alliance (BRTA), Leonardo Da Vinci 11, 01510 Miñano, Spain; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain, Pedraz JL; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain; Bioaraba Health Research Institute, Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain.

Publikováno v: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Sep; Vol. 373, pp. 463-480. Date of Electronic Publication: 2024 Jul 25.

Principal Features of Industry-Funded Trials that Posted Informed Consent Forms on ClinicalTrials.gov: a Cross-Sectional Analysis.

Autor: Dal-Ré R; Biostatistics and Epidemiology Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Avda Reyes Católicos 2, Madrid, ES-28040, Spain. rafael.dalre@quironsalud.es., Mahillo-Fernández I; Biostatistics and Epidemiology Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Avda Reyes Católicos 2, Madrid, ES-28040, Spain.

Publikováno v: The AAPS journal [AAPS J] 2024 Jun 18; Vol. 26 (4), pp. 72. Date of Electronic Publication: 2024 Jun 18.

Designs of clinical swallowability assessments of solid oral dosage forms in regulatory submissions.

Autor: McGuire MR; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Mostofa A; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Shon J; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Frost M; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Kim MJ; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Li K; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: karen.li@fda.hhs.gov.

Publikováno v: International journal of pharmaceutics [Int J Pharm] 2024 Jun 25; Vol. 659, pp. 124229. Date of Electronic Publication: 2024 May 16.